From: The role of IL-4 gene polymorphism in HCV-related hepatocellular carcinoma in Egyptian patients
polymorphism -589 C/T (rs2243250) | Control n = 30(%) | LC n = 40 (%) | HCC n = 50 (%) | p value | LC vs control | HCC vs. control | HCC vs. LC | |||
---|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | p value | |||||
Genotypes | Â | 0.044 | Â | Â | Â | Â | Â | Â | ||
CC | 15 (50.0) | 19 (47.5) | 18 (36.0) |  | Ref | – | Ref | – | Ref | – |
CT | 14 (46.7) | 19 (47.5) | 20 (40.0) |  | 1.07 (0.41–2.82) | 0.889 | 1.19 (0.45–3.13) | 0.724 | 1.11 (0.45–2.73) | 0.818 |
TT | 1 (3.3) | 2 (5.0) | 12 (24.0) |  | 1.58 (0.13–19.12) | 1.000 | 10.0 (1.16–86.02) | 0.018 | 6.33 (1.24–32.32) | 0.016 |
Dominant model | Â | Â | Â | 0.391 | Â | Â | Â | Â | Â | Â |
CC | 15 (50.0) | 19 (47.5) | 18 (36.0) |  | Ref | – | Ref | – | Ref | – |
CT+TT | 15 (50.0) | 21 (52.5) | 32 (64.0) |  | 1.11 (0.43–2.85) | 0.836 | 1.78 (0.71–4.46) | 0.218 | 1.61 (0.69 – 3.76) | 0.271 |
Recessive model | Â | Â | Â | 0.008 | Â | Â | Â | Â | Â | Â |
CC+CT | 29 (96.7) | 38 (96.0) | 38 (76.0) |  | Ref | – | Ref | – | Ref | – |
TT | 1 (3.3) | 2 (5.0) | 12 (24.0) |  | 1.53 (0.13–17.66) | 1.000 | 9.16 (1.13–74.52) | 0.025 | 6.00 (1.26–28.64) | 0.013 |
Alleles | Â | Â | Â | 0.034 | Â | Â | Â | Â | Â | Â |
C | 44 (73.3) | 57 (71.3) | 56 (56.0) |  | Ref | – | Ref | – | Ref | – |
T | 16 (26.7) | 23 (28.8) | 44 (44.0) |  | 1.11 (0.52–2.35) | 0.786 | 2.16 (1.08–4.33) | 0.028 | 1.95 (1.04–3.64) | 0.035 |